News
Presentations at WHS and SAWC to highlight EscharEx’s mechanism of action, preclinical advantages over SANTYL®, and new data ...
A global Phase III study in venous leg ulcers (VLUs) is currently underway, with a Phase II/III study in diabetic foot ulcers (DFUs) in preparation. EscharEx has shown clinical advantages over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback